Our team has completed data curation for all FDA drug approvals in 2025, including 34 NDAs and 12 BLAs. You can access the complete list and explore their detailed DMPK data, DDI evaluations, drug characteristics, DDI summaries, and QT assessments.
Among the small‑molecule drugs (N = 34), nearly half (N = 16) included PBPK-supported DDI assessments that informed dose recommendations in labeling. In addition, PBPK modeling was applied to two BLAs, both for ADCs, to support DDI predictions for the small‑molecule payloads in these conjugates. You can also access this subset of drugs directly on the page above by applying the PBPK filter.